A colloidal particle and a preparation method and application of the induced self-assembly into capsid

By aminolated polycyclodextrin-tanninic colloidal particles, the problem of insufficient acid resistance and adhesion during oral administration is solved, and higher survival rate and intestinal The ability to colonize the Tao improves the bioavailability of drugs.

CN115957343BActive Publication Date: 2024-11-12DALIAN UNIV OF TECH
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202211549177.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-05
Publication Date
2024-11-12
Estimated Expiration
2042-12-05

AI Technical Summary

Technical Problem

In the prior art, probiotics are easily killed by gastric acid and bile salt during oral administration, and are difficult to colonize in the intestines. The stability and adhesion properties of commonly used encapsulation materials are insufficient, resulting in low bioavailability.

Method used

Aminolated polycyclodextrin-tanninic acid colloidal particles are used to form capsids through the action of the host and guest, and probiotics are embedded, and self-assembly is used to induce self-assembly to form a dense shell layer, which improves the acid resistance and adhesion ability of probiotics.

Benefits of technology

It improves the survival rate and intestinal colonization ability of probiotics in the gastrointestinal environment, provides stronger protection effects, and enhances the bioavailability of drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115957343B_ABST
    Figure CN115957343B_ABST
Patent Text Reader

Abstract

The present invention discloses a colloidal particle and a preparation method and application of the induced self-assembly capsid thereof, belonging to the technical field of biofunctional materials. The colloidal particles of the present invention are non-biotoxic and do not cause immune response and tissue damage in mice. The method provided by the present invention for the self-assembly of negatively charged drug-induced colloidal particles to form a capsid does not require a cross-linking agent, has high encapsulation efficiency, high raw material utilization rate, and has the advantages of low cost, simple operation, and strong protective ability. Compared with the traditional method, the method for preparing the self-assembly capsid of the negatively charged drug-induced colloidal particles of the present invention can obtain a thick and dense capsid, provide a stronger ability to protect drugs from the invasion of the gastrointestinal environment, and promote the colonization of oral probiotics in the intestine, and is expected to be used for oral drugs to treat related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biofunctional materials and relates to a preparation method and application of a biomaterial for oral drug delivery. Background Art

[0002] For drugs that are acid-intolerant or require intestinal absorption, oral administration has disadvantages such as low bioavailability and severe gastric irritation. In recent years, a large number of studies have shown that probiotics can regulate the host's intestinal flora and systemic immune function, promote nutrient absorption and maintain intestinal health. Therefore, more and more probiotic drugs are being developed to treat gastrointestinal diseases.

[0003] However, during oral administration, the bactericidal ability of the highly acidic gastric juice in the stomach and bile salts in the intestines kills most probiotics, making it difficult for them to play a beneficial role in the intestine. Even if a small number of probiotics survive, it is still difficult for them to attach to the surface of the intestine for colonization due to their short residence time, which greatly limits the beneficial functions of probiotics.

[0004] Therefore, in the process of oral delivery of such drugs, drug embedding and encapsulation technology has been developed to improve its resistance to gastric acid. In the prior art, probiotic embedding and encapsulation technology is mainly based on alginate and its complexes. Sodium alginate is a natural polysaccharide present in the cell wall of brown algae, which has high biocompatibility and is easy to form gels with cations. Since sodium alginate colloid will cause the gel stability to decrease in the presence of high-affinity ions or high-concentration non-ionic gel inducers, sodium alginate is often combined with a single or multiple combination of various traditional natural polymer wall materials such as chitosan, starch, gelatin or whey protein according to the different biological properties of the encapsulated core material. However, the pores of the hydrogel cannot effectively prevent the killing of probiotics by hydrogen ions and bile salts, and these commonly used encapsulation materials have no adhesion properties, which makes it difficult for probiotics to adhere and colonize in the intestine. In addition, at the technical level, there are defects such as difficult to control the size of microcapsules, low encapsulation efficiency of hydrogels, or harmful crosslinking agents. Summary of the invention

[0005] The purpose of the present invention is to provide a colloidal particle, which can self-assemble on the surface of negatively charged particles to form a capsid, so as to encapsulate drugs such as probiotics that are not acid-resistant and need to be absorbed through the intestine, so as to solve the problems existing in the prior art.

[0006] The present invention is achieved through the following technical solutions:

[0007] A kind of aminated polycyclodextrin-tannic acid colloidal particles, comprising aminated polycyclodextrin and tannic acid, wherein the cyclodextrin cavity in the aminated polycyclodextrin and the pyrogallol unit of the tannic acid form colloidal particles through host-guest interaction. The aminated polycyclodextrin-tannic acid colloidal particles have good stability and size uniformity, and have a certain positive electrical energy and can be induced by negatively charged drugs to self-assemble into capsids. The aminated polycyclodextrin-tannic acid colloidal particles have no biological toxicity and do not cause immune response and tissue damage in mice.

[0008] Furthermore, the aminated polycyclodextrin includes ethylenediamine aminated polycyclodextrin, butylenediamine aminated polycyclodextrin and hexamethylenediamine aminated polycyclodextrin.

[0009] Furthermore, the concentration of the amino polycyclodextrin is 1 to 15 mg mL -1 ; The concentrations of aminated polycyclodextrin and tannic acid are the same, and the volume ratio of the two is 2:1. When the ratio of aminated polycyclodextrin to tannic acid increases, the relative content of tannic acid decreases, which is insufficient to connect different polycyclodextrin segments, and colloidal particles cannot be formed; when the ratio of aminated polycyclodextrin to tannic acid decreases, the relative content of tannic acid increases, and excessive polycyclodextrin segments are connected, causing colloidal particles to aggregate.

[0010] Furthermore, the diameter of the aminated polycyclodextrin-tannic acid colloidal particles ranges from 15 to 50 nm, and the diameter of the aminated polycyclodextrin-tannic acid colloidal particles is controlled by controlling the concentration of the aminated polycyclodextrin.

[0011] A method for preparing the above-mentioned aminated polycyclodextrin-tannic acid colloidal particles by self-assembly to form a drug capsid, wherein the aminated polycyclodextrin-tannic acid colloidal particles are assembled onto the drug surface to form a capsid through the electrostatic attraction of negatively charged drugs, and specifically comprises the following steps:

[0012] (1) adding the frozen probiotics to Luria-Bertani (LB) medium, activating at 37° for 5 hours at a rotation speed of 200 rpm, taking out and centrifuging and rinsing with deionized water three times to prepare a probiotic solution; or adding heparin to deionized water to prepare a heparin solution.

[0013] (2) Adding the probiotic bacterial liquid or heparin solution to the amino polycyclodextrin-tannic acid colloidal particles, rapidly oscillating, the positively charged amino polycyclodextrin-tannic acid colloidal particles self-assemble on the surface of the probiotics or heparin to form a capsid; then centrifuging to remove the unreacted colloidal particles, washing three times with deionized water, and obtaining the probiotics or heparin with the capsid.

[0014] Furthermore, in step (1), the probiotics include Escherichia coli Nissle 1917 (EcN) or Bacillus coagulans (BC).

[0015] Furthermore, in step (1), the concentration of the prepared probiotic solution is 5×10 8 ~5×10 9 CFU mL -1 , preferably 8×10 8 ~2×10 9 CFU mL -1 .

[0016] Furthermore, in step (1), the heparin concentration prepared is 5 to 15 mg mL -1 , preferably 8-12 mg / mL -1 .

[0017] Furthermore, in step (2), the centrifugal rotation speed is 500 to 3000 rpm, preferably 800 to 1200 rpm.

[0018] Furthermore, in step (2), the concentration of the amino polycyclodextrin-tannic acid colloidal particles is 5 to 15 mg / mL -1 The volume ratio of the amino polycyclodextrin-tannic acid colloidal particles to the probiotic solution or heparin solution is 3:1.

[0019] Amino-modified polycyclodextrin carries a certain positive charge, and the cyclodextrin provides a guest cavity for tannic acid to perform host-guest interaction. The host-guest interaction and positive charge repulsion between tannic acid and polycyclodextrin reach a balance to form colloidal particles. The abundant phosphocholic acid phosphate groups in the bacterial cell wall make the bacterial surface negatively charged, which can shield the electrostatic repulsion between positively charged colloidal particles. Negatively charged probiotics or heparin can induce colloidal particles to self-assemble into a dense and thick shell to encapsulate them.

[0020] Application of a capsid formed by self-assembly of amino-polycyclodextrin-tannic acid colloidal particles in oral drug delivery.

[0021] Beneficial effects of the present invention: The colloidal particles of the present invention have no biological toxicity and do not cause immune response and tissue damage in mice. The method provided by the present invention for the self-assembly of negatively charged drug-induced colloidal particles to form capsids does not require a cross-linking agent, has high encapsulation efficiency, high raw material utilization rate, and has the advantages of low cost, simple operation, and strong protective ability. Compared with the traditional method, the present invention can prepare negatively charged drug-induced colloidal particle self-assembly capsids, obtain thick and dense capsids, provide stronger ability to protect drugs from the gastrointestinal environment, and promote the colonization of oral probiotics in the intestine, and is expected to be used for oral drug treatment of related diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 Schematic diagram of probiotic-induced colloidal particles self-assembly to form capsids.

[0023] Figure 2 These are laser confocal images of probiotics-induced colloidal particles self-assembling to form capsids; (a) is the probiotic EcN, (b) is the capsid formed by NTc, (c) is the probiotic NTcEcN protected by the capsid, and (d) is the cross-section of NTcEcN.

[0024] Figure 3 The figures are statistical diagrams showing the protective ability of the capsid on the probiotic EcN in simulated gastric fluid and bile salt environments; (a) shows the survival of the probiotic EcN in simulated gastric acid, and (b) shows the survival of the probiotic EcN in bile salts.

[0025] Figure 4 Fluorescent images of the enhanced adhesion ability of the capsid to probiotic EcN in a simulated intestinal environment; (a) shows the enhanced ability of the capsid to probiotic EcN under static adhesion, and (b) shows the enhanced ability of the capsid to probiotic EcN under dynamic adhesion.

[0026] Figure 5 Fluorescence images of the enhanced adhesion ability of the capsid on the probiotic EcN in mice; (a) is the fluorescence imaging of the whole mouse, and (b) is the fluorescence imaging of the intestinal tissue of the mouse.

[0027] Figure 6 This is a graph showing the effectiveness of capsid-encapsulated probiotic EcN in treating Salmonella-induced enteritis in mice.

[0028] Figure 7 The particle size and surface potential of the colloidal particles formed by polycyclodextrin and tannic acid modified with different diamines; (a) is the particle size of the colloidal particles, and (b) is the potential of the colloidal particles.

[0029] Figure 8 The figures show the binding capacity between polycyclodextrins modified with different diamines and tannic acid, and the protective capacity of the formed colloidal particles on probiotics; (a) shows the survival of probiotic EcN in simulated gastric acid, and (b) shows the survival of probiotic BC in simulated gastric acid.

[0030] Fig. 9 It is the absorbance value of the suspension formed after heparin-induced colloidal particle self-assembly at 600nm. DETAILED DESCRIPTION

[0031] Hereinafter, examples are given to illustrate the specific embodiments of the present invention, but the embodiments of the present invention are not limited by the following examples, and any selection and change can be made within the scope that does not affect the technical effects to be achieved by the present invention. If no specific conditions are specified in the embodiments and test examples, the conventional conditions or the conditions recommended by the manufacturer are followed, and the reagents or instruments used without indicating the manufacturer are all conventional products that can be obtained commercially.

[0032] Example 1

[0033] The colloidal particles selected in this embodiment are colloidal particles formed by ethylenediamine-aminated polycyclodextrin and tannic acid. The probiotic Escherichia coli Nissle1917 (EcN) purchased from the China General Microbiological Culture Collection Center is used as a model to illustrate and verify the probiotic protection and probiotic colonization promotion system of the present invention, which includes the following steps:

[0034] 1. Preparation of colloidal particles formed by amino polycyclodextrin and tannic acid

[0035] (1) Preparation of amino polycyclodextrin (NPCD)

[0036] Dissolve 2.0 g of polycyclodextrin (PCD) and 3.0 g of ethylenediamine (EDA) in 10 mL of deionized water; stir the reaction solution in an oil bath at 40°C for 24 h, then add the reaction solution dropwise into ethanol to obtain a precipitate of ethylenediamine-amino-polycyclodextrin; then wash the obtained ethylenediamine-amino-polycyclodextrin repeatedly with ethanol for 3 times, vacuum dry it at 50°C overnight, and store it at 4°C before use.

[0037] (2) Formation of colloidal particles by aminated polycyclodextrin with ethylenediamine and tannic acid

[0038] The ethylenediamine-aminated polycyclodextrin (400 μL, the specific concentration is shown in Table 1) prepared in step (1) was added to an aqueous solution of tannic acid (200 μL, the specific concentration is shown in Table 1), the concentrations were kept the same, and the mixture was shaken for 10 seconds to obtain colloidal particles.

[0039] Next, the colloidal particles prepared above were tested by a dynamic light scattering instrument. The dynamic light scattering data showed the particle sizes of the colloidal particles prepared by amino polycyclodextrin with different concentrations. The parameters are shown in Table 1:

[0040] Table 1 Relationship between particle size and concentration of colloidal particles prepared by amino polycyclodextrin and tannic acid

[0041]

[0042] 2. Prepare the probiotic samples to be protected

[0043] The probiotic EcN was cultured in LB medium for 5 hours at 37°C and a shaking speed of 200 rpm. It was then collected by centrifugation at 5000 rpm for 3 minutes, washed three times with deionized water, and finally resuspended with deionized water to obtain different concentrations of EcN probiotic solutions (concentrations were 5×10 8 CFUs mL -1 , 1×10 9 CFUs mL -1 , 5×10 9 CFUs mL -1 ).

[0044] 3. Probiotics induce colloidal particles to assemble and form capsids

[0045] 200 μL of the three concentrations of EcN probiotics were added to three different concentrations of ethylenediamine amino polycyclodextrin-tannic acid colloidal particles (600 μL, concentrations of 5, 10, and 15 mg / mL, respectively) prepared in step 1. -1 ) and immediately mixed vigorously with a vortex mixer for 10 seconds. Then centrifuged at different speeds (500, 1000, and 3000 rpm) for 3 minutes, washed with deionized water three times, and stored at 4°C before use. 9 CFUs mL -1 , the colloidal particle concentration is 10 mg mL -1 When the centrifugal speed is 1000 rpm, the capsid quality obtained is the best.

[0046] Figure 1 The process of probiotic-induced colloidal particles self-assembling to form capsids was clearly demonstrated; Figure 2 The laser confocal image shown shows that the concentration of EcN probiotic solution is 1×10 9 CFUs mL -1 , the colloidal particle concentration is 10 mg mL -1 The capsid diameter is about 15 μm, and the cross-section image shows that the probiotics are evenly encapsulated in the capsid.

[0047] 4. Experiment on the protection of probiotics by capsid in simulated gastric fluid and bile salt environment

[0048] The capsid-encapsulated Escherichia coli Nissle 1917 (NTcEcN) was incubated in simulated gastric fluid (pH 2.0, containing pepsin) and bile salts (4% w / v) for 2 hours, then centrifuged at 5000 rpm for 3 minutes, washed with deionized water 3 times, and plated with gradient dilutions. After 24 hours, the survival rate was counted and calculated. At the same time, a commercial enteric polymer was selected L100 (L100) was used to wrap EcN (L100EcN) for comparison. Figure 3 As shown, the unencapsulated probiotics had almost no survival in simulated gastric fluid, and the survival rate in bile salts was 28%; the survival rate of L100-encapsulated probiotics L100EcN in both simulated gastric fluid and bile salts was improved; and the NTc capsid-encapsulated probiotics NTcEcN showed stronger survival ability in simulated gastric fluid and bile salts. Statistics showed that its survival rate in simulated gastric fluid was as high as 19%, and its survival rate in bile salts reached 63%.

[0049] 5. Experiment on the enhanced adhesion ability of capsid on probiotics in simulated intestinal environment

[0050] Static Adhesion:

[0051] First, mucin was labeled with the red fluorescent dye TRITC. Specifically, TRITC solution (1 mg mL -1 ,DMSO) was dripped into the mucin solution (2 mg mL -1 , pH 9) with a molar ratio of 1:10. The mixed solution was reacted in the dark at 4°C for 12 hours, and then the reaction solution was dialyzed with deionized water and freeze-dried to obtain TRITC-labeled mucin. The membrane formed by the colloidal particles (NTc film) was then immersed in a TRITC-labeled mucin solution (1 mg mL -1 , pH 6.8) at 37°C for 1 h. The films were rinsed three times with deionized water and imaged under an inverted fluorescence microscope. Figure 4 As shown in (a), the fluorescence intensity of mucin adhered to the NTc film is about 7 times that of mucin adhered to the L100 film, indicating the strong binding ability of NTc to mucin.

[0052] Dynamic Adhesion:

[0053] First, immerse the glass slide in PEI solution (2 mg mL -1 ) for 1 h, then rinsed three times with deionized water; then -1 ) for another hour and rinse with deionized water. 9 CFU mL -1 The suspension of SYTO9 was dropped onto a mucin-coated glass slide, and then the non-adherent EcNs were removed by rinsing with deionized water and observed under an inverted fluorescence microscope. Figure 4 As shown in (b), the amount of NTcEcN adhered to the mucin surface increased significantly, which was mainly attributed to the strong adhesion ability of tannic acid in NTc to protein.

[0054] 6. Fluorescence imaging of the enhanced adhesion of probiotics to mice

[0055] NTcEcN was delivered into mice by oral gavage, and the fluorescence intensity of the whole mouse and the removed intestine was observed by mouse imaging system 4 hours later. Figure 5 As shown, the fluorescence intensity of NTcEcN in the intestine was significantly higher than that of EcN alone, indicating the enhanced adhesion ability of NTcEcN in the mouse intestine.

[0056] 7. Data on the effect of capsid-encapsulated probiotics in treating Salmonella-induced enteritis in mice

[0057] First, mice were gavaged with 1×10 9 CFU of Salmonella was used to induce enteritis model, and then 1×10 9 CFU of NTcEcN was used for treatment. The number of Salmonella in the body changes as Figure 6 As shown in the figure, as the treatment time prolonged, the number of Salmonella in the mice gradually decreased. On the seventh day, the number of Salmonella in the mice was about two orders of magnitude lower than that of the untreated mice.

[0058] Example 2

[0059] The colloidal particles selected in this embodiment are colloidal particles formed by aminated polycyclodextrin with butanediamine and aminated polycyclodextrin with hexamethylenediamine and tannic acid, respectively. Escherichiacoli Nissle 1917 (ECN) and Bacillus coagulans (BC) purchased from the China General Microbiological Culture Collection Center are used as probiotic models to illustrate and verify the probiotic protection and probiotic colonization promotion system of the present invention, which includes the following steps:

[0060] 1. Preparation of colloidal particles formed by amino polycyclodextrin and tannic acid

[0061] (1) Preparation of amino polycyclodextrins (NPCDs)

[0062] Dissolve 2.0g PCD and 3.0g diaminobutane (DAB) or diaminohexane (DAH) in 10mL deionized water; stir the reaction solution in a 40°C oil bath for 24h, then add the reaction solution dropwise into ethanol to obtain a precipitate of diaminobutane or diaminohexane polycyclodextrin; wash the obtained diamino polycyclodextrin repeatedly with ethanol for 3 times. The obtained diamino polycyclodextrin was vacuum dried at 50°C overnight and stored at 4°C before use.

[0063] (2) Aminated polycyclodextrin and tannic acid form colloidal particles

[0064] Polycyclodextrins (400 μL, 10 mg mL-1 ) was added to tannic acid (200 μL, 10 mg mL -1 ) aqueous solution, shake for 10 seconds to obtain colloidal particles, and store them at 4°C.

[0065] Next, the colloidal particles prepared above were randomly selected and tested using a dynamic light scattering instrument. Figure 7 The dynamic light scattering data clearly show that the particle size of the colloidal particles is about 30nm and has a certain positive charge.

[0066] 2. Prepare the probiotic samples to be protected

[0067] The method is the same as in Example 1.

[0068] 3. Probiotics induce colloidal particles to assemble and form capsids

[0069] The method is the same as in Example 1.

[0070] 4. Experiment on the protection of probiotics by capsid in simulated gastric fluid:

[0071] The method is the same as in Example 1. Figure 8 As shown, the capsids formed by cyclodextrins aminated with butanediamine and hexamethylenediamine have relatively good protection effects on EcN or BC.

[0072] Example 3

[0073] The negatively charged particles selected in this embodiment are negatively charged heparin, which is encapsulated by colloidal particles formed by ethylenediamine-aminated polycyclodextrin and tannic acid, comprising the following steps:

[0074] 1. Preparation of colloidal particles formed by amino polycyclodextrin and tannic acid

[0075] The method is the same as in Example 1.

[0076] 2. Heparin-induced colloidal particle assembly to form capsid

[0077] Three concentrations of heparin solution (200 μL, concentrations of 5, 10, 15 mg mL -1 ) were added to three concentrations of ethylenediamine-amino polycyclodextrin and tannic acid colloidal particles (600 μL, concentrations of 5, 10, and 15 mg mL -1 ) and immediately mixed vigorously with a vortex mixer for 10 seconds. 200 μL of the mixture was placed in a 96-well plate and the absorbance at 600 nm (OD 600 nm) was measured. Fig. 9 As shown, the colloidal particles (10 mg mL -1 ) Add heparin (10 mg mL -1), the absorbance of the solution at 600 nm increased dramatically, indicating that heparin successfully induced the aggregation of colloidal particles to form aggregates of larger particles, which led to an increase in turbidity.

Claims

1. An amino polycyclodextrin-tannic acid colloidal particle, characterized in that: The colloidal particles include aminated polycyclodextrin and tannic acid, and the cyclodextrin cavity in the aminated polycyclodextrin and the pyrogallol unit of the tannic acid form colloidal particles through host-guest interaction; in, The aminated polycyclodextrin includes ethylenediamine aminated polycyclodextrin, butanediamine aminated polycyclodextrin and hexamethylenediamine aminated polycyclodextrin; The concentration of the amino polycyclodextrin is 1-15 mg mL -1 ; The concentrations of amino polycyclodextrin and tannic acid are the same, and the volume ratio between the two is 2:

1.

2. The aminated polycyclodextrin-tannic acid colloidal particles according to claim 1, characterized in that: The diameter of the amino polycyclodextrin-tannic acid colloidal particles ranges from 15 to 50 nm.

3. A method for preparing a drug capsid formed by self-assembly of colloidal particles as claimed in claim 1, characterized in that: The method comprises the following steps: (1) The frozen probiotics were added to Luria-Bertani medium and activated at 37° for 5 hours at a speed of 200 rpm. After removal, they were centrifuged and rinsed three times with deionized water to a concentration of 5×10 8 ~5×10 9 CFU mL -1 or add heparin to deionized water to prepare a concentration of 5-15 mg mL -1 of heparin solution; (2) Adding the probiotic bacterial solution or heparin solution to the amino polycyclodextrin-tannic acid colloidal particles and rapidly shaking, the positively charged amino polycyclodextrin-tannic acid colloidal particles self-assemble on the surface of the probiotics or heparin to form a capsid; then centrifuging to remove the unreacted colloidal particles, washing three times with deionized water, and obtaining the probiotics or heparin with the capsid.

4. The preparation method according to claim 3, characterized in that: In the step (2), the concentration of the amino polycyclodextrin-tannic acid colloidal particles is 5-15 mg mL -1 The volume ratio of the amino polycyclodextrin-tannic acid colloidal particles to the probiotic solution or the amino polycyclodextrin-tannic acid colloidal particles to the heparin solution is 3:

1.

5. The preparation method according to claim 3, characterized in that: In step (1), the concentration of the probiotic solution is 8×10 8 ~2×10 9 CFU mL -1 The concentration of heparin solution is 8-12 mg mL -1 .

6. The preparation method according to claim 3, characterized in that: The probiotics include Escherichia coli Nissle 1917 or Bacillus coagulans .

7. The preparation method according to claim 3, characterized in that: In the step (2), the centrifugal speed is 500-3000 rpm.

8. Use of the capsid obtained by the preparation method according to any one of claims 3 to 7 in preparing a biological material for oral drug delivery.

Citation Information

Patent Citations

  • Polyphenol coating for capturing circulating tumor cells

    CN108531455A

  • Cyclodextrin polymers and cyclodextrins immobilized on a solid surface

    US5262404A

  • Cyclodextrins preferentially substituted on their primary face by acid or amine functions

    US6524595B1

  • Probe compound for detecting and isolating enzymes and means and methods using the same

    WO2010105851A1

  • KR20210101102A